COMMUNIQUÉS West-GlobeNewswire
-
Insider tradings
16/11/2017 - 16:20 -
New data shows more needs to be done to keep kids with diabetes safe at school
16/11/2017 - 16:00 -
Premier Biomedical Appoints Carl Eller, NFL Retired Players Association President, as Marketing & Planning Vice-President
16/11/2017 - 16:00 -
Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer
16/11/2017 - 15:25 -
Zomedica Pharmaceuticals Corp. Expects Trading of its Common Shares on the NYSE American to Commence on November 21, 2017
16/11/2017 - 15:12 -
MRI Interventions’ ClearPoint® NeuroNavigation System Achieves 2000th Procedure Milestone
16/11/2017 - 15:00 -
IDVV announces OTC Markets Tier Upgrade as Part of Planned Company Restructure
16/11/2017 - 15:00 -
OrthoPediatrics Corp. to Participate in the 29th Annual Piper Jaffray Healthcare Conference
16/11/2017 - 15:00 -
AxoGen, Inc. Announces Pricing of Public Offering of Common Stock
16/11/2017 - 14:40 -
Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting
16/11/2017 - 14:30 -
Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors
16/11/2017 - 14:30 -
Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
16/11/2017 - 14:30 -
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
16/11/2017 - 14:30 -
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
16/11/2017 - 14:00 -
Prothena Highlights Breadth of Novel Pipeline at R&D Day
16/11/2017 - 14:00 -
Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients
16/11/2017 - 14:00 -
Interpace Diagnostics Announces New York State Approval of New Product
16/11/2017 - 14:00 -
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
16/11/2017 - 13:45 -
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
16/11/2017 - 13:30
Pages